A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced ige antibodies

Journal of Infectious Diseases

Volumn 186, Issue 9, 2002, Pages 1261-1269

  Kweon, Mi Na ^a   Yamamoto, Masafumi ^a,b   Watanabe, Fumiko ^c   Tamura, Shinichi ^d   Van Ginkel, Frederik W ^g   Miyauchi, Akira ^c   Takagi, Hiroaki ^c   Takeda, Yoshifumi ^d   Hamabata, Takashi ^e   Fujihashi, Kohtaro ^g   McGhee, Jerry R ^g   Kiyono, Hiroshi ^a,f,g  

^a OSAKA UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c Higeta Shoyu Co Ltd   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; ENTEROTOXIN; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; TETANUS TOXIN; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BREVIBACCILLUS CHOSHINENSIS; BREVIBACTERIUM; CHIMERA; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INFLUENZA VIRUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAFETY; TETANUS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODY FORMATION; BACTERIAL TOXINS; BASE SEQUENCE; CHOLERA TOXIN; CLONING, MOLECULAR; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN E; MICE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROTEIN SUBUNITS; RECOMBINANT FUSION PROTEINS; RESTRICTION MAPPING;

EID: 0036838682     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344526     Document Type: Article

References (41)

1. McGhee JR, Kiyono H. The mucosal immune system. In: Paul WE, ed. Fundamental Immunology. 4th Ed. Philadelphia: Lippincott-Raven, 1999: 909-30.
2. Yamamoto M, McGhee JR, Hagiwara Y, Otake S, Kiyono H. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand J Immunol 2001; 53:211-7.
3. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 1992; 56:622-47.
4. de Haan L, Verweij WR, Feil IK, et al. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect Immun 1996; 64:5413-6.
5. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995; 63:1617-23.
6. Douce G, Turcotte C, Cropley I, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995; 92:1644-8.
7. Fontana MR, Manetti R, Giannelli V, et al. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect Immun 1995; 63:2356-60.
8. Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187:1123-32.
9. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992; 22:2277-81.
10. Pizza M, Fontana MR, Giuliani MM, et al. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med 1994; 180:2147-53.
11. Yamamoto S, Takeda Y, Yamamoto M, et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 1997; 185:1203-10.
12. Saito M, Otake S, Ohmura M, et al. Protective immunity to Strepzococcus mutants induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant. J Infect Dis 2001; 183:823-6.
13. Yamamoto S, Kiyono H, Yamamoto M, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997; 94:5267-72.
14. Yamamoto M, Briles DE, Yamamoto S, Ohmura M, Kiyono H, McGhee JR. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol 1998; 161:4115-21.
15. Hagiwara Y, Komase K, Chen Z, et al. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine. Vaccine 1999; 17: 2918-26.
16. Dalls WS, Falkows S. Cistrons encoding Escherichia coli heat-labile toxin. J Bacteriol 1979; 139:850-5.
17. Ebisu S, Tsuboi A, Takagi H, et al. Conserved structures of cell wall protein genes among protein-producing Bacillus brevis strains. J Bacteriol 1990; 172:1312-20.
18. Takagi H, Kagiyama S, Kadowaki K, Tsukagoshi N, Udaka S. Genetic transformation of Bacillus brevis with plasmid DNA by electroporation. Agric Biol Chem 1989; 53:3099-105.
19. Miyauchi A, Ozawa M, Mizukami M, et al. Structural conversion from nonnative to native form of recombinant human epidermal growth factor by Brevibacillus choshinensis. Biosci Biotechnol Biochem 1999; 63:1965-9.
20. Kajino T, Ohto C, Muramatsu M, et al. A protein disulfide isomerase gene fusion expression system that increases the extracellular productivity of Bacillus brevis. Appl Environ Microbiol 2000; 66:638-42.
21. Uesaka Y, Otsuka Y, Lin Z, et al. Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb Pathog 1994; 16:71-6.
22. Fujita K, Finkelstein RA. Antitoxic immunity in experimental cholera: Comparison of immunity induced perorally and parenterally in mice. J Infect Dis 1972; 125:647-55.
23. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165:4778-82.
24. Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett CD, Lease GO. Comparison of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinin. J Lab Clin Med 1964; 63:5-13.
25. Tamura S, Ito Y, Asanuma H, et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 1992; 149:981-8.
26. Tamura S, Miyata K, Matsuo K, et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 1996; 156: 3892-900.
27. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR. Optimizing oral vaccines: Induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 1993; 61:4272-9.
28. + Th2 cells play a central role in STAT6-mediated allergic diarrhea. J Clin Invest 2000; 106:199-206.
29. Yetter RA, Lehrer S, Ramphal R, Small PA Jr. Outcome of influenza infection: Effect of site of initial infection and heterotypic immunity. Infect Immun 1980; 29:654-62.
30. Tobita K. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol (Berl) 1975; 162: 23-7.
31. Tobita K, Sugiura A, Enmote C, Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol (Berl) 1975; 162:9-14.
32. Gorbach SL, Khurana CM. Toxigenic Escherichia coli in infantile diarrhea in Chicago. J Lab Clin Med 1971; 78:981-2.
33. Rowe B, Taylor J, Bettelheim KA. An investigation of traveller's diarrhea. Lancet 1970; 1:1-5.
34. Sack RB, Gorbach SL, Banwell JG, Jacobs B, Chatterjee BD, Mitra RC. Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J Infect Dis 1971; 123:378-85.
35. Di Tommaso A, Saletti G, Pizza M, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996;64:974-9.
36. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995;96:563-5.
37. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 1993; 91:867-72.
38. Kumagai T, Yamanaka T, Wataya Y, et al. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol 1997; 100:130-4.
39. Hagiwara Y, Iwasaki T, Asanuma H, et al. Effects of intranasal administration of cholera toxin (of Escherichia coli heat-labile enterotoxin) B sub-units supplemented with a trace amount of the holotoxin on the brain. Vaccine 2001; 19:1652-60.
40. Udaka S, Tsukagoshi N, Yamagata H. Bacillus brevis, a host bacterium for efficient extracellular production of useful proteins. Biotechnol Genet Eng Rev 1989;7:113-46.
41. Udaka S, Yamagata H. High-level secretion of heterologous proteins by Bacillus brevis. Methods Enzymol 1993; 217:23-33.